85916-13-8

Basic information

• Product Name: DI-TERT-BUTYL IMINODIACETATE
• Synonyms: DI-TERT-BUTYL IMINODIACETATE;N-BIS(T-BUTYLACETATE)AMINE;Iminodiacetic Acid Di-tert-butyl Ester;Di-tert-butyl 2,2'-azanediyldiacetate;(tert-Butoxycarbonylmethylamino)acetic acid tert-butyl ester;Di-tert-butyl 2,2'-iminobis[acetate];Di-tert-butyl iminodiacetate 98%;Di-tert-butyl Iminodiacetate
• CAS NO: 85916-13-8
• Molecular Formula: C₁₂H₂₃NO₄
• Molecular Weight: 245.32
• Product Categories: C12 to C63;Carbonyl Compounds;Esters;Building Blocks;C12 to C63;Carbonyl Compounds;Chemical Synthesis;Organic Building Blocks
• Mol File: 85916-13-8.mol
• Article Data: 11

Chemical Properties

• Melting Point: 38-42 °C(lit.)
• Boiling Point: 298.0±25.0 °C(Predicted)
• Flash Point: >230 °F
• Appearance: /
• Density: 1.011±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• Solubility: soluble in Methanol
• PKA: 4.52±0.20(Predicted)
• CAS DataBase Reference: DI-TERT-BUTYL IMINODIACETATE(CAS DataBase Reference)
• NIST Chemistry Reference: DI-TERT-BUTYL IMINODIACETATE(85916-13-8)
• EPA Substance Registry System: DI-TERT-BUTYL IMINODIACETATE(85916-13-8)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• WGK Germany: 3
• Hazardous Substances Data: 85916-13-8(Hazardous Substances Data)

Usage

Uses

Di-tert-butyl iminodiacetate may be used as a reagent in the synthesis of:multi-carboxylic acid-containing carbocyanine dyesmonosubstituted difunctionalized polyhedral oligomeric silsesquioxanes (POSS) monomersmultigenerational fluorinated dendrimers2,6-dipyrazol-1-ylpyridine derivativesIt may also be used for the preparation of di-tert-butyl N-(4-allyloxy-4-oxobutanoyl)iminodiacetate.

General Description

Di-tert-butyl iminodiacetate is a secondary amine.

Upstream product

• 540-88-5 acetic acid tert-butyl ester 
• 142-73-4 iminodiacetic acid 
• 75-65-0 tert-butyl alcohol 
• 5292-43-3 bromoacetic acid tert-butyl ester 
• 100-46-9 benzylamine 
• 107-59-5 tert-Butyl chloroacetate 
• 58482-93-2 tert-butylaminoacetic acid 
• 275371-57-8 di-tert-butyl 2,2'-(benzylimino)diacetate 

Downstream Products

• 518286-93-6 di-tert-butyl 2-[1-[2-[4-(N-(p-tolyl)-2-furancarboxamido)piperidin-1-yl]ethyl]cyclohexyl]acetyliminodiacetate 
• 1276694-13-3 C₁₉H₂₈N₂O₆ 
• 1354022-89-1 C₄₁H₅₇N₃O₁₁ 
• 1354022-84-6 C₃₃H₅₄N₂O₉ 
• 1446687-62-2 di-tert-butyl 2,2'-(((4-((4-aminophenyl)ethynyl)-6-(((2-(bis(2-(tert-butoxy)-2-oxoethyl)amino)-ethyl)(2-(tert-butoxy)-2-oxoethyl)amino)methyl)pyridin-2-yl)methyl)azanediyl)diacetate 

Relevant articles and documents

Preparation method of di-tert-butyl iminodiacetate

The invention discloses a preparation method of di-tert-butyl iminodiacetate. The method is characterized in that ammonia and tert-butyl chloroacetate are used as raw materials. The method comprises the following steps: carrying out a reaction between ammonia and tert-butyl chloroacetate based on the molar ratio of 1:(1-6) in an organic solvent under a closed condition, wherein the reaction temperature is 10-65 DEG C, the reaction pressure is normal pressure, and the reaction lasts for 2-10h; after the reaction ends, cooling until the room temperature is reached; filtering; rotatably evaporating the filtrate to remove the organic solvent; then cooling to reach the temperature of 0 DEG C to obtain a solid which is di-tert-butyl iminodiacetate. According to the method, the solvent is nontoxic and free of pollution; the solvent is recycled; no catalyst or cocatalyst is used; the reaction separation method is simple; the di-tert-butyl iminodiacetate yield is high.

GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS WITH IMPROVED SOLUBILITY

The invention relates to derivatives of glycopeptide and lipoglycopeptide antibiotics possessing an altered ionization state with respect to the parent glycopeptide or lipoglycopeptide antibiotic, and having the ability to be regenerated as the parent gly

SUBSTITUTED PROPIONYL DERIVATIVES

The present invention relates to a compound represented by the following formula (1): [wherein, X1represents a carboxyl group which may be esterified or the like group; Y1represents a single bond, -O- or -N(R1)-; at least one of A1, A2and A3is a group represented by the following formula (2): -R2-a1-R3-a2→{wherein, R2represents a divalent C2-12hydrocarbon group, R3represents a single bond or a divalent C1-12hydrocarbon group, a1and a2individually represent a single bond, -S-, -SO-, -SO2-, -SO2NH-, -O-, -N(R4)-, -CON(R5)-, -C(=O)- or - Si(R6)(R7)- and → means bonding with Q1, Q2or Q3}, the remaining one or two of A1, A2and A3are the same or different and each independently represents a group represented by the following formula (3): -R8-a3-R9-a4→{wherein, R8and R9individually represent a single bond or a divalent C1-12hydrocarbon group, a3and a4individually represent a single bond, -S-, -SO-, -SO2-, -SO2NH-, -O-, - N(R10)-, -CON(R11)-, -C(=O)- or -SI(R12)(R13)- and → means bonding with Q1, Q2or Q3},; at least one of Q1, Q2and Q3represents a cyclic hydrocarbon group or heterocyclic group and the remaining one or two of Q1, Q2and Q3individually represent a hydrogen atom, a carboxyl group which may be esterified, a hydrocarbon group or a heterocyclic group] or salt thereof; and a pharmaceutical comprising the same as an effective ingredient. The compound exhibits strong squalene synthetase inhibitory action and is therefore useful as a pharmaceutical for the treatment·prevention of hypercholesterolemia, hyperlipemia or arteriosclerosis.